Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.
Chetouani A,de Saint Basile G,Fischer A,Fusaro M,Guerin F,Lévy R,Moshous D,Neven B,Sepulveda F
Source :
Blood Adv
2020 Avr 10
Pmid / DOI:
32271897
Abstract
First evidence of ruxolitinib efficacy for subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis. Supporting rationale for ruxolitinib use, not more aggressive treatment, in this context, questioning this condition’s neoplastic nature.